Variables | Value | Range | Distribution | Reference |
---|---|---|---|---|
Clinical event probabilities (monthly) | Â | Â | Â | Â |
Progression disease | Â | Â | Â | Â |
abiraterone group | 0.0047 | 0.00423–00517 | beta | [27] |
enzalutamide group | 0.0024 | 0.00216-.00264 | beta | Â |
Death in progression state | Â | Â | Â | Â |
abiraterone group | 0.0019 | 0.00171-.00209 | beta | [27] |
enzalutamide group | 0.0021 | 0.00189-.0023 | beta | Â |
Death in progression free survival state | Â | Â | Â | Â |
abiraterone group | 0.009 | 0.0081-.0099 | beta | [27] |
enzalutamide group | 0.008 | 0.0072-.0088 | beta | Â |
AE*in abiraterone group (monthly) | Â | Â | Â | Â |
Anemia | 0.007 | 0.006-.008 | beta | [28] |
Backpain | 0.033 | 0.028-.038 | beta | [28] |
Bone pain | 0.084 | 0.071-.097 | beta | [29] |
Diarrhea | 0.018 | 0.015-.021 | beta | [28] |
Fatigue | 0.05 | 0.043-.058 | beta | [28] |
Neutropenia | 0.003 | 0.0026-.0035 | beta | [28] |
Vomiting | 0.022 | 0.019-.025 | beta | [28] |
AE in enzalutamide group (monthly) | Â | Â | Â | Â |
Anemia | 0.005 | 0.004-.006 | beta | |
Backpain | 0.084 | 0.071-.097 | beta | |
Arthralgia | 0.017 | 0.014-.02 | beta | |
Diarrhea | 0.013 | 0.011-.015 | beta | |
Fatigue | 0.033 | 0.028-.038 | beta | |
vomiting | 0.02 | 0.017-.023 | beta | |
Utility | Â | Â | Â | Â |
Progression-free | 0.61 | 0.55-.68 | beta | [32] |
progression | 0.31 | 0.28-.35 | beta | [32] |
Disutility anemia | 0.11 | 0.099-.12 | beta | [32] |
Disutility backpain | 0.06 | 0.054-.066 | beta | [32] |
Disutility bone pain | 0.06 | 0.054-.066 | beta | [32] |
Disutility diarrhoea | 0.2 | 0.18-.22 | beta | [32] |
Disutility fatigue | 0.47 | 0.42-.52 | beta | [32] |
Disutility neutropenia | 0.1 | 0.09-.12 | beta | [32] |
Disutility arthralgia | 0.041 | 0.035-.047 | beta | [33] |
Disutility vomiting | 0.09 | 0.07-.104 | beta | [33] |
Cost ($) | Â | Â | Â | Â |
enzalutamide | 24$ | 19.2–28.8 | gamma | |
abiraterone | 13$ | 10.4–15.6 | gamma | |
Laboratory tests | 319$ | 255–386 | gamma | |
Imaging | 213$ | 170–255 | gamma | |
Bone protecting agent | 3,400$ | 2,720-4,080 | gamma | |
Radiopharmaceutical | 6,853$ | 5,482-8,223 | gamma | |
Hospitalization | 1,763$ | 1,410-2,115 | gamma | |
Chemotherapy | 10,287 $ | 8,229 − 12,324 | gamma | |
Anemia | 166$ | 141–191 | gamma | |
Backpain | 84$ | 71–95 | gamma | |
Bone pain | 95$ | 81–109 | gamma | |
Diarrhea | 52$ | 44–60 | gamma | |
Fatigue | 131$ | 111–151 | gamma | |
Neutropenia | 154$ | 131–177 | gamma | |
Vomiting | 85$ | 72–98 | gamma | |
Direct non-medical cost | Â | Â | Â | Â |
enzalutamide group | 1,549 $ | 1,239-1,858 | gamma | Interview |
abiraterone group | 2,132 $ | 1,705-2,558 | gamma | Â |
Indirect cost | Â | Â | Â | Â |
enzalutamide group | 5,179 $ | 4,143-6,214 | gamma | Interview |
abiraterone group | 6,906 $ | 5,524-8,287 | gamma | Â |